We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+67.05%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$486M
AUM Growth
+$109M
Cap. Flow
+$86.4M
Cap. Flow %
17.77%
Top 10 Hldgs %
56.66%
Holding
71
New
17
Increased
8
Reduced
9
Closed
6

Top Buys

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$61.6M
2
KERX
Keryx Biopharmaceuticals Inc
KERX
+$15.3M
3
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$12.9M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$8.22M
5
BMY icon
Bristol-Myers Squibb
BMY
+$7.49M

Top Sells

Rank Stock Value
1
QCOR
QUESTCOR PHARMA INC
QCOR
+$18.5M
2
CELG
Celgene Corp
CELG
+$17.2M
3
OMER icon
Omeros
OMER
+$8.05M
4
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$7.2M
5
MRK icon
Merck
MRK
+$5.79M

Sector Composition

Rank Sector Weight
1 Healthcare 79.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
26
Nektar Therapeutics
NKTR
$2.39B
$5.43M 1.12%
+30,000
New +$5.74M
SGMO
27
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$5.39M 1.11%
500,000
– –
CBPO
28
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$5.13M 1.05%
95,000
-5,000
-5% -$246K
EGRX
29
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$5.06M 1.04%
400,000
– –
PTLA
30
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$5.06M 1.04%
200,000
– –
QTNT
31
DELISTED
Quotient Limited Ordinary Shares
QTNT
$4.71M 0.97%
12,500
– –
SRNE
32
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$4.52M 0.93%
1,000,000
– –
ALKS icon
33
Alkermes
ALKS
$8.22B
$4.29M 0.88%
100,000
– –
ALNY icon
34
Alnylam Pharmaceuticals
ALNY
$27.5B
$3.9M 0.8%
50,000
– –
ARAV
35
DELISTED
Aravive, Inc. Common Stock
ARAV
$3.8M 0.78%
33,333
– –
RMTI icon
36
Rockwell Medical
RMTI
$28.4M
$3.66M 0.75%
3,636
– –
ARRY
37
DELISTED
Array Biopharma Inc
ARRY
$3.57M 0.73%
1,000,000
– –
IMDZ
38
DELISTED
Immune Design Corp.
IMDZ
$3.53M 0.73%
+200,000
New +$2.53M
NSTG
39
DELISTED
NanoString Technologies, Inc.
NSTG
$3.28M 0.68%
300,000
– –
CBIO
40
Crescent Biopharma
CBIO
$535M
$3.28M 0.67%
4,723
– –
KIN
41
DELISTED
Kindred Biosciences, Inc.
KIN
$3.24M 0.67%
350,000
+250,000
+250% +$3.38M
CLVS
42
DELISTED
Clovis Oncology, Inc.
CLVS
$3.17M 0.65%
70,000
– –
KITE
43
DELISTED
Kite Pharma, Inc.
KITE
$2.85M 0.59%
+100,000
New +$2.47M
GNVC
44
DELISTED
GenVec, Inc.
GNVC
$2.77M 0.57%
132,930
– –
ASPX
45
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$2.57M 0.53%
100,000
– –
GALT icon
46
Galectin Therapeutics
GALT
$196M
$2.27M 0.47%
450,400
-349,600
-44% -$2.72M
ADVM
47
DELISTED
Adverum Biotechnologies
ADVM
$2.22M 0.46%
+6,500
New +$1.93M
SCTL
48
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$2.07M 0.43%
780,500
+223,000
+40% +$1.08M
AGEN
49
Agenus
AGEN
$312M
$2.02M 0.42%
33,118
-12,737
-28% -$798K
NGNE icon
50
Neurogene
NGNE
$656M
$2M 0.41%
15,000
– –
1
2
3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q3 2014 Portfolio in Review

As of Q3 2014, Cormorant Asset Management held 71 positions worth $486M, up 29% from $377M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Cormorant Asset Management deployed $86.4M of net new capital in Q3 2014, opening 17 new positions and adding to 8 existing holdings. Its largest new stake was Keryx Biopharmaceuticals Inc: 1,000,000 shares worth $13.8M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 78% a quarter earlier.

On the sell side, the largest reduction was Omeros, an estimated $8.05M trimmed.

  • Cormorant Asset Management's largest Q3 2014 buy was Keryx Biopharmaceuticals Inc: 1,000,000 shares worth $13.8M.
  • Cormorant Asset Management added most to Puma Biotechnology in Q3 2014, an estimated $61.6M increase.
  • Cormorant Asset Management's biggest Q3 2014 reduction was Omeros, cutting an estimated $8.05M.
  • Cormorant Asset Management fully exited QUESTCOR PHARMA INC in Q3 2014, selling an estimated $18.5M.
  • Cormorant Asset Management's ten largest holdings make up 57% of its $486M portfolio in Q3 2014.
  • Cormorant Asset Management opened 17 new positions and closed 6 in Q3 2014.
  • Cormorant Asset Management's portfolio value rose 29% quarter-over-quarter to $486M.

Based on Cormorant Asset Management's 13F filing for Q3 2014, filed 14 Nov 2014.